Latest Commercial Growth News

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

Papyrus Australia has taken a significant step towards commercialisation by signing a $4.2 million supply contract with TBS Mining Solutions for its biodegradable Collar Keeper® products, while advancing its Adelaide R&D facility.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

6K Additive has landed a landmark US$27.4 million loan from the US Export-Import Bank, partnering with the Department of War to fund a major expansion in Pennsylvania that will quintuple powder production capacity and create over 50 new jobs.

Titomic Limited has successfully completed a hot fire test on a solid rocket motor thrust chamber made with its Titomic Kinetic Fusion cold spray technology, marking a significant milestone in aerospace additive manufacturing.

Oneview Healthcare reported robust commercial growth in 2025, driven by new US client wins and the launch of its AI-powered care assistant, Ovie. The company enters 2026 with a confident outlook focused on expanding its US footprint and advancing digital health innovation.

Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.

First Graphene Limited has raised A$3.5 million through a share placement to accelerate the commercial adoption of its PureGRAPH graphene products and support ongoing operations.

InteliCare successfully completed its largest aged care pilot at mecwacare’s Trescowthick Centre and secured $2 million in funding, while navigating a key leadership transition.

Acrux Limited reports robust revenue growth in Q1 FY26, driven by strong profit share income from recently launched topical pharmaceuticals and a significant R&D tax rebate repayment.

Alexium International Group reported a 26% rise in Q1 FY26 sales driven by new business wins and expanded foam bedding applications, while navigating tighter funding conditions.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.